28
Oct
2025
Innate Immune System Activators for Cancer: Art Krieg on The Long Run
Art Krieg is today’s guest on The Long Run. Art is the founder and CEO of a Cambridge, Mass.-based startup called Zola Therapeutics. Zola is developing an oligonucleotide drug candidate to activate a family of Toll-like receptors known as TLR7 TLR8 and TLR9. Activating these receptors is thought to spur the innate immune system to attack cancer cells. Art designed... Read More